15 juli 2012: een reviewstudie naar resultaten met het reovirus bij verschillende vormen van kanker heeft hoopgevende conclusie: The extensive pre-clinical efficacy, replication competency, and low toxicity profile in humans has placed the reovirus as an attractive anti-cancer therapeutic for ongoing clinical testing.
Oncolytic viral therapy using reovirus.
Tom Baker Cancer Centre, Department of Medicine and Oncology, University of Calgary, Alberta, Canada.
Current mainstays in cancer treatment such as chemotherapy, radiation therapy, hormonal manipulation, and even targeted therapies such as trastuzumab (Herceptin) for breast cancer or erlotinib (Tarceva) for non-small cell lung cancer are limited by lack of efficacy, cellular resistance, and toxicity. Dose escalation and combination therapies designed to overcome resistance and increase efficacy are limited by a narrow therapeutic index. Oncolytic viruses are one such group of new biological therapeutics that appears to have a wide spectrum of anticancer activity with minimal human toxicity. Because the malignant phenotype of tumours is the culmination of multiple mutations that occur in several genes eventually leading to aberrant signalling pathways, oncolytic viruses, either natural or engineered, specifically target tumour cells, taking advantage of this cellular deviant signalling for their replication. Reovirus is one such naturally occurring double-stranded RNA (dsRNA) virus that exploits altered Ras signalling pathways in a myriad of cancers. The ability of reovirus to infect and lyse tumours both solid and haematological, under in vitro, in vivo, and ex vivo conditions, is discussed in this chapter. The major mechanism of reovirus oncolysis of cancer cells has been shown to occur through apoptosis. In addition, the synergistic anti-tumour effects of reovirus in combination with radiation or chemotherapy has also been demonstrated for reovirus-resistant and moderately sensitive tumours. In most of the clinical trials undertaken to date, an anti-reovirus immune response has been seen likely circumventing efficacy. Investigation into the use of reovirus as an immune adjuvant is currently underway to try and re-direct this immune response to tumour. Reovirus phase I clinical trials have shown indications of efficacy and several phase I/II trials are ongoing at present. The extensive pre-clinical efficacy, replication competency, and low toxicity profile in humans has placed the reovirus as an attractive anti-cancer therapeutic for ongoing clinical testing.
- [PubMed - indexed for MEDLINE]
7 november 2009: Bron: Oncolytics.com
Reolysin zorgt voor significant betere resultaten als vaccin ingezet bij soft sarcoma's aldus fase II studie met 44 patienten en gepresenteerd door het bedrijf dat het Reovirus als vaccin inzet. Volgens het bedrijf bewerkstelligden 19 van de 44 deelnemende patienten een stabiele ziekte van 2 tot 20 maanden met enkelen zelfs een gedeelteljike remissie van 19 en 20 maanden.
|11/6/2009 9:08:01 AM ET||
|Oncolytics Biotech® Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting|
|CALGARY, AB, November 6, 2009 --- Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) (“Oncolytics” or the “Company”) today announced updated results from a Phase II study of intravenous REOLYSIN® in patients with sarcomas metastatic to the lung in a poster presentation at the 15th Annual Connective Tissue Oncology Society Meeting held in Miami Beach, Florida, from November 5th to 7th. The poster presentation, entitled "A Phase II Study of Intravenous REOLYSIN (Wild-type Reovirus) in the Treatment of Patients with Bone and Soft Tissue Sarcomas Metastatic to the Lung", was delivered by Dr. Kamalesh Sankhala, part of principal investigator Dr. Monica Mita's team at the Institute of Drug Development (IDD), the Cancer Therapy and Research Center at the University of Texas Health Science Center, (UTHSC), San Antonio, Texas.
The investigators reported that the treatment has been well tolerated to date, and that 19 of 44 evaluable patients experienced stable disease ranging from two to 20 months, resulting in a total clinical benefit rate (complete response + partial response + stable disease) of 43%. The response objective for the study was three or more patients having prolonged stabilization of disease (>6 months) or better, for the agent to be considered. The trial exceeded its established objective with six patients experiencing stable disease for more than six months. Two patients have experienced stable disease for more than 19 months. One has synovial cell sarcoma that relapsed following surgery, while the other has Ewing’s Sarcoma and had previously progressed following multiple treatments.
“We were very happy to participate in the study,” said Dr. Mita. “REOLYSIN is a promising option for patients with sarcoma as shown by the results of this study. As a single agent the virus had a clinical benefit rate of 43% and it was very well tolerated. Further studies combining REOLYSIN with chemotherapy are contemplated in order to integrate the virus in the panoply of agents used for sarcoma treatment.”
“These results are consistent with what we observed on an interim basis when we reported data on the first 16 patients back in June 2008,” said Dr. Brad Thompson, President and CEO of Oncolytics. “It is encouraging that we are observing stable disease in a range of sarcomas and the clinical benefit is not isolated to any specific type.”
- Virusinjectie (REOLYSIN) geeft in fase I studie veelbelovende resultaten bij kankerpatiënten met solide tumoren Artikel geplaatst december 2005
- REOLYSIN: Virusinjectie geeft in verschillende studies veelbelovende resultaten bij kankerpatiënten. O.a. bij hoofd- halstumoren - melanomen - longkanker en sarcoma's.
- REOLYSIN virus ingezet als vaccin, bereikt goede resultaten bij soft sarcoma's. Aldus een kleinschalige fase II trial.
- Reolysin, een overzicht van recente ontwikkelingen en belangrijke studies met dit virus medicijn